Pfizer, J&J report ominous PhIII failure of bapineuzumab in ... FierceBiotech "While we are disappointed in the topline results of Study 302, a more complete understanding of bapineuzumab and its potential utility in mild-to-moderate Alzheimer's disease will be gained following the availability of additional data, including data...
No comments:
Post a Comment